FinnCap Reaffirms Corporate Rating for Evgen Pharma (LON:EVG)

FinnCap reaffirmed their corporate rating on shares of Evgen Pharma (LON:EVG) in a research report released on Wednesday, ThisIsMoney.Co.Uk reports.

EVG stock opened at GBX 17.13 ($0.22) on Wednesday. The stock has a 50 day moving average of GBX 17.67. Evgen Pharma has a fifty-two week low of GBX 13.10 ($0.17) and a fifty-two week high of GBX 33 ($0.43). The company has a market cap of $22.72 million and a PE ratio of -6.34.

About Evgen Pharma

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.

See Also: What is the significance of a dead cat bounce?

Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.